Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

doi:10.1200/JCO.2014.58.2007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Mar 2015

Lopez-Chavez Ariel, Thomas Anish, Rajan Arun, Raffeld Mark, Morrow Betsy, Kelly Ronan, Carter Corey Allan, Guha Udayan, Killian Keith, Lau Christopher C, Abdullaev Zied, Xi Liqiang, Pack Svetlana, Meltzer Paul S, Corless Christopher L, Sandler Alan, Beadling Carol, Warrick Andrea, Liewehr David J, Steinberg Seth M, Berman Arlene, Doyle Austin, Szabo Eva, Wang Yisong, Giaccone Giuseppe

Abstract excerpt

PURPOSE: We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently. PATIENTS AND METHODS: We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Lapatinib

Share to Pyrroles

Share to Quinazolines

Share to Small Cell Lung Carcinoma

Share to Sunitinib

Share to Thymus Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25667274
DOI: 10.1200/JCO.2014.58.2007
PMCID: PMC4356709

Genes

EGFR
KRAS
ALK
BRAF
ERBB2
HRAS
KIT
NRAS
PDGFRA
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.PMID 25667274Read ↗

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

Revolutionizing cancer drug development: Harnessing the potential of basket trials.Semantic proximity Read ↗

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven OncologySemantic proximity Read ↗

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.Semantic proximity Read ↗

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Semantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkersSemantic proximity Read ↗

LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?Semantic proximity Read ↗

Innovative Clinical Trials: The LUNG-MAP Study.Semantic proximity Read ↗

The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.Semantic proximity Read ↗

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.